Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADMA ADMA Biologics	$17.88 -2.2%	$20.11	$10.21 ▼ $25.67	$4.36B	0.43	3.69 million shs	1.83 million shs
CASI CASI Pharmaceuticals	$1.33 +2.2%	$1.70	$1.09 ▼ $7.67	$15.99M	0.53	50,693 shs	21,731 shs
SRRK Scholar Rock	$35.48 -1.4%	$32.47	$6.76 ▼ $46.98	$3.42B	0.33	1.29 million shs	751,489 shs
STRO Sutro Biopharma	$0.74 -2.9%	$0.86	$0.52 ▼ $5.17	$64.46M	1.64	1.13 million shs	720,669 shs
TCRR TCR2 Therapeutics	$1.48	$1.65	$0.82 ▼ $3.88	$58.11M	1.95	494,777 shs	N/A

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADMA ADMA Biologics	-2.27%	-1.81%	-13.25%	+0.11%	+56.02%
CASI CASI Pharmaceuticals	-0.08%	+12.63%	-28.62%	-35.01%	-76.81%
SRRK Scholar Rock	+0.37%	+0.17%	+3.65%	+44.99%	+358.40%
STRO Sutro Biopharma	-3.16%	+3.77%	-12.64%	+16.64%	-74.63%
TCRR TCR2 Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADMA ADMA Biologics	4.1343 of 5 stars	3.7	2.0	0.0	0.0	3.0	2.5	3.1
CASI CASI Pharmaceuticals	4.0974 of 5 stars	3.5	5.0	0.0	4.3	0.6	1.7	0.0
SRRK Scholar Rock	3.3172 of 5 stars	2.6	0.0	0.0	4.4	1.1	3.3	0.6
STRO Sutro Biopharma	3.1689 of 5 stars	3.1	1.0	0.0	4.7	0.6	1.7	0.0
TCRR TCR2 Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADMA ADMA Biologics	3.33	Buy	$27.67	54.74% Upside
CASI CASI Pharmaceuticals	3.00	Buy	$4.00	200.98% Upside
SRRK Scholar Rock	3.14	Buy	$42.67	20.26% Upside
STRO Sutro Biopharma	2.25	Hold	$6.11	725.36% Upside
TCRR TCR2 Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest ADMA, STRO, CASI, SRRK, and TCRR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/18/2025	SRRK Scholar Rock	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$50.00
6/16/2025	STRO Sutro Biopharma	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$2.00
6/3/2025	SRRK Scholar Rock	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/19/2025	CASI CASI Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $4.00
5/19/2025	STRO Sutro Biopharma	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underperform ➝ Underperform	$1.00 ➝ $0.80
5/14/2025	SRRK Scholar Rock	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$50.00
5/8/2025	ADMA ADMA Biologics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Strong-Buy ➝ Strong-Buy	$25.00 ➝ $32.00
4/29/2025	STRO Sutro Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$2.00 ➝ $2.00
4/9/2025	CASI CASI Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$6.00 ➝ $4.00

(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADMA ADMA Biologics	$426.45M	10.01	$0.53 per share	33.77	$1.48 per share	12.08
CASI CASI Pharmaceuticals	$31.37M	0.52	N/A	N/A	$0.12 per share	11.08
SRRK Scholar Rock	$33.19M	101.50	N/A	N/A	$3.94 per share	9.01
STRO Sutro Biopharma	$62.04M	1.01	N/A	N/A	$0.54 per share	1.37
TCRR TCR2 Therapeutics	N/A	N/A	N/A	N/A	$2.58 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADMA ADMA Biologics	$197.67M	$0.85	21.04	25.91	N/A	45.01%	47.16%	30.51%	8/6/2025 (Estimated)
CASI CASI Pharmaceuticals	-$39.26M	-$2.55	N/A	∞	N/A	-129.05%	-972.55%	-77.33%	8/15/2025 (Estimated)
SRRK Scholar Rock	-$246.29M	-$2.53	N/A	N/A	N/A	N/A	-118.22%	-82.01%	8/6/2025 (Estimated)
STRO Sutro Biopharma	-$227.46M	-$2.98	N/A	N/A	N/A	-373.66%	-347.60%	-59.46%	8/12/2025 (Estimated)
TCRR TCR2 Therapeutics	-$151.82M	-$4.20	N/A	N/A	N/A	N/A	-97.81%	-69.35%	N/A

Latest ADMA, STRO, CASI, SRRK, and TCRR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/16/2025	Q1 2025	CASI CASI Pharmaceuticals	-$0.61	-$0.69	-$0.08	-$0.69	$7.39 million	$6.24 million
5/14/2025	Q1 2025	SRRK Scholar Rock	-$0.63	-$0.67	-$0.04	-$0.67	N/A	N/A
5/8/2025	Q1 2025	STRO Sutro Biopharma	-$0.63	-$0.91	-$0.28	-$0.91	$11.61 million	$17.40 million
5/7/2025	Q1 2025	ADMA ADMA Biologics	$0.16	$0.14	-$0.02	$0.11	$116.40 million	$114.80 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADMA ADMA Biologics	N/A	N/A	N/A	N/A	N/A
CASI CASI Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SRRK Scholar Rock	N/A	N/A	N/A	N/A	N/A
STRO Sutro Biopharma	N/A	N/A	N/A	N/A	N/A
TCRR TCR2 Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADMA ADMA Biologics	0.22	6.58	3.36
CASI CASI Pharmaceuticals	N/A	0.81	0.68
SRRK Scholar Rock	0.16	10.25	10.25
STRO Sutro Biopharma	N/A	2.16	2.16
TCRR TCR2 Therapeutics	N/A	2.96	2.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADMA ADMA Biologics	75.68%
CASI CASI Pharmaceuticals	22.23%
SRRK Scholar Rock	91.08%
STRO Sutro Biopharma	96.99%
TCRR TCR2 Therapeutics	64.76%

Insider Ownership

Company	Insider Ownership
ADMA ADMA Biologics	3.70%
CASI CASI Pharmaceuticals	21.24%
SRRK Scholar Rock	13.30%
STRO Sutro Biopharma	5.90%
TCRR TCR2 Therapeutics	25.01%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADMA ADMA Biologics	530	238.73 million	229.90 million	Optionable
CASI CASI Pharmaceuticals	180	12.30 million	9.69 million	Optionable
SRRK Scholar Rock	140	94.95 million	82.32 million	Optionable
STRO Sutro Biopharma	240	84.46 million	79.48 million	Optionable
TCRR TCR2 Therapeutics	137	39.26 million	29.44 million	Not Optionable

ADMA, STRO, CASI, SRRK, and TCRR Headlines

Recent News About These Companies

TCR2 Therapeutics gets grant for recombinant nucleic acid encoding TCR fusion protein for cancer treatment

April 17, 2024 | pharmaceutical-technology.comP

Poseida Therapeutics Inc Ordinary Shares PSTX

February 25, 2024 | morningstar.comM

DICE Therapeutics Inc.

June 20, 2023 | wsj.com

Adaptimmune Announces Completion of Strategic Combination with TCR2 Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company

June 1, 2023 | finance.yahoo.com

TCR2 Therapeutics Insider Trades Send a Signal

May 16, 2023 | benzinga.com

Recap: TCR2 Therapeutics Q1 Earnings

May 12, 2023 | msn.com

10-Q: TCR2 THERAPEUTICS INC.

May 11, 2023 | marketwatch.com

TCR² Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 11, 2023 | finance.yahoo.com

Companies Like TCR2 Therapeutics (NASDAQ:TCRR) Could Be Quite Risky

April 15, 2023 | finance.yahoo.com

Mizuho Downgrades Tcr2 Therapeutics (TCRR)

March 25, 2023 | msn.com

TCR2 Therapeutics (TCRR) was downgraded to a Hold Rating at Mizuho Securities

March 23, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: TCR2 Therapeutics (TCRR) and Inozyme Pharma (INZY)

March 23, 2023 | markets.businessinsider.com

TCR2 Therapeutics: TCR² Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update

March 23, 2023 | finanznachrichten.de

TCR² Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update

March 23, 2023 | finance.yahoo.com

What To Know About Jefferies's Downgrade of TCR2 Therapeutics

March 9, 2023 | msn.com

4 Analysts Have This to Say About TCR2 Therapeutics

March 9, 2023 | markets.businessinsider.com

TCR2 Therapeutics (TCRR) was downgraded to a Hold Rating at H.C. Wainwright

March 8, 2023 | markets.businessinsider.com

Shareholder Alert: Ademi LLP investigates whether TCR² Therapeutics Inc. has obtained a Fair Price in its transaction with Adaptimmune

March 6, 2023 | benzinga.com

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating TCR² Therapeutics Inc. Buyout

March 6, 2023 | benzinga.com

Why Is TCR2 Therapeutics (TCRR) Stock Up 30% Today?

March 6, 2023 | investorplace.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
3 AI Infrastructure Stocks With Strong Growth, Not Hype
By Chris Markoch | June 26, 2025
View 3 AI Infrastructure Stocks With Strong Growth, Not Hype
These 3 Dividend Stocks Combine Strong Yields With Upside
By Chris Markoch | June 20, 2025
View These 3 Dividend Stocks Combine Strong Yields With Upside
Chime’s Smart IPO: Half the Valuation, Double the Strength
By Jeffrey Neal Johnson | June 18, 2025
View Chime’s Smart IPO: Half the Valuation, Double the Strength
Super Micro Computer Stock's Rally Backed by Strong Financials
By Gabriel Osorio-Mazilli | June 19, 2025
View Super Micro Computer Stock's Rally Backed by Strong Financials

ADMA, STRO, CASI, SRRK, and TCRR Company Descriptions

ADMA Biologics NASDAQ:ADMA

$17.88 -0.40 (-2.19%)

Closing price 07/7/2025 04:00 PM Eastern

Extended Trading

$18.31 +0.43 (+2.40%)

As of 07/7/2025 07:28 PM Eastern

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

CASI Pharmaceuticals NASDAQ:CASI

$1.33 +0.03 (+2.23%)

Closing price 07/7/2025 03:55 PM Eastern

Extended Trading

$1.33 +0.00 (+0.08%)

As of 07/7/2025 05:50 PM Eastern

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc?RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. The company has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.

Scholar Rock NASDAQ:SRRK

$35.48 -0.51 (-1.42%)

Closing price 07/7/2025 04:00 PM Eastern

Extended Trading

$35.59 +0.11 (+0.31%)

As of 07:04 AM Eastern

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Sutro Biopharma NASDAQ:STRO

$0.74 -0.02 (-2.94%)

Closing price 07/7/2025 04:00 PM Eastern

Extended Trading

$0.76 +0.02 (+3.13%)

As of 07:05 AM Eastern

Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

TCR2 Therapeutics NASDAQ:TCRR

TCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. It is also involved in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development. The company was founded by Patrick A. Baeuerle on May 29, 2015 and is headquartered in Cambridge, MA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time